PT-141 side effects.

Most common PT-141 side effects

Nausea, flushing, injection-site reactions and headache are the main bremelanotide side effects. In the two controlled Vyleesi trials, nausea affected 40.0% of participants, flushing 20.3%, injection-site reactions 13.2% and headache 11.3%. Vomiting occurred in 4.8%. [1]

FDA label data for premenopausal women with acquired, generalized HSDD using the trial medication. These percentages describe participants over follow-up, not the chance after every injection. Events can overlap. They do not establish adverse-event rates for the supplied research vial or nasal spray. [1]

Cough, fatigue, hot flushes, tingling and nasal congestion also occurred in at least 2% of the treatment group. The original RECONNECT report describes most treatment-emergent events as mild or moderate, but symptoms still caused some participants to stop. [2]

Nausea: timing and what helps

Nausea usually began within an hour and lasted about two hours in the trial data. It was most frequent after the first administration. That typical pattern does not guarantee that an individual episode will be short, or that every later dose will be symptom-free. [1]

For mild queasiness, sit quietly, take small regular sips of fluid and choose light, bland food such as toast or crackers. Avoid a large greasy meal, strong food smells and lying flat immediately after eating. These are general nausea-care measures; they have not been proven to eliminate bremelanotide nausea. [3]

Repeated vomiting changes the problem. Seek medical advice if liquids will not stay down, urination becomes markedly reduced or weakness is increasing. A person with fluid restrictions or kidney or heart disease needs individualized advice rather than a generic large fluid target.

Does ondansetron prevent PT-141 nausea?

Routine ondansetron pretreatment did not prevent it in the study cited by the current label. In 228 healthy women, an 8 mg oral dose 30 minutes before 1.75 mg bremelanotide did not significantly reduce nausea compared with placebo pretreatment. That preventive approach is not recommended in the prescribing information. [1]

A clinician may consider treatment for nausea after symptoms arise or discontinue bremelanotide if nausea is persistent or severe. The label specifically notes that ondansetron given after bremelanotide or after nausea begins has not been formally studied. An online claim that it reliably solves the problem overstates the evidence.

Nausea is an adverse effect, not a target or a sign of a stronger sexual response. Do not add an extra dose because nausea occurred without the desired benefit. The dose and timing page explains the 24-hour interval and monthly limit.

Flushing, headache and dizziness

A warm face or temporary redness can occur without an allergy. Flushing was usually not serious in the registration studies. Breathing difficulty, throat swelling or collapse requires a different response and should never be grouped with ordinary warmth. [1]

Headache and lightheadedness can interrupt the planned activity even when a treatment is helping desire. Rest somewhere safe if dizzy, and have severe, persistent or unusual symptoms assessed. Avoid treating the intensity of a headache as proof that the product is active or correctly dosed.

A healthcare professional needs to know about other medicines, alcohol and any blood-pressure measurements when assessing a reaction. A familiar mild headache is different from a sudden severe headache with weakness, vision changes, difficulty speaking or chest symptoms. Those signs need urgent medical assessment. [4]

Blood pressure rises while heart rate can fall

Bremelanotide can temporarily raise blood pressure and reduce heart rate. The label describes maximum increases of approximately 6 mmHg systolic and 3 mmHg diastolic, with heart rate decreasing by up to 5 beats per minute. Blood-pressure changes peaked around two to four hours and usually returned to baseline within twelve hours. [1]

A separate trial monitored blood pressure over the day in 397 women with normal pressure or controlled hypertension. It detected small temporary increases with the higher studied amounts and a reduced pulse. This supports checking cardiovascular health rather than relying on whether someone feels a racing heartbeat. [5]

Uncontrolled hypertension and known cardiovascular disease are contraindications to Vyleesi. High cardiovascular risk also warrants avoiding it under the label's recommendation. Taking an extra blood-pressure tablet independently is not a workaround. Blood-pressure treatment and suitability for bremelanotide need clinician review.

Closer repeat doses can increase the pressure-related risk. A calendar date change does not create a new 24-hour interval, and tolerating the first administration does not establish that an additional same-day dose is safe.

Dark spots, gums and skin pigmentation

Bremelanotide can darken patches of skin, including the face, gums and breasts. Focal pigmentation was reported in about 1% of participants using up to eight doses per month. More frequent dosing and darker skin increased the concern. Some changes had not been confirmed to resolve after stopping. [1]

Daily administration produced a very different result in a separate study: 38% developed pigmentation after eight consecutive days. Among those who continued for another eight days, an additional 14% developed new changes. That experiment is a reason to avoid converting an on-demand medicine into a daily course.

Report a new dark patch to the prescriber and discuss whether treatment should stop. A pigment change is not a desired tanning benefit or a reliable indicator of peptide purity. Increasing sun protection does not establish that continued dosing will reverse a drug-related change.

Oral medicines, naltrexone and alcohol

Bremelanotide can slow stomach emptying and change how some oral medicines are absorbed. The important examples include naltrexone and indomethacin. The label advises avoiding use alongside oral drugs that rely on reaching a threshold concentration, such as certain antibiotics, and reviewing treatment when an oral medicine's rapid effect is needed. [1]

Avoid Vyleesi with oral naltrexone-containing treatment for alcohol or opioid addiction. Reduced naltrexone exposure can undermine that treatment. Do not stop naltrexone in order to take bremelanotide; bring both prescriptions to the treating clinician. Every naltrexone-containing product should be included in the medication review.

The official HCP information describes no alcohol restriction for prescribed Vyleesi, based partly on a small interaction study. That is not proof that heavy drinking is harmless or that alcohol will reduce nausea. If nausea or dizziness is already present, alcohol can make managing the situation harder. [6] [3]

Do not assume that a nasal route avoids interactions. The formulation, amount absorbed and other medicines still matter. A pharmacist can review the complete list, including nonprescription drugs and supplements.

Pregnancy, contraception and breastfeeding

Stop prescribed Vyleesi if pregnancy is suspected, and contact the prescriber. Effective contraception is advised during treatment. The available human pregnancy experience is too limited to establish safety; animal studies found developmental harm at high exposures. [1]

The October 2026 label includes new human breastfeeding information. After one 1.75 mg dose in ten lactating women, the estimated relative infant dose was 0.132% of the mother's weight-adjusted dose. Milk concentrations were below the assay's measurement limit at 24 hours. Infant outcomes were not evaluated and effects on milk production remain unknown.

That small single-dose study supports a more specific discussion with the clinician; it does not establish repeated-use safety for every mother and infant. It also does not validate a research nasal formulation or a self-selected dose. Do not turn the 24-hour sample result into an invented mandatory breastfeeding interruption rule.

Kidney disease, liver disease and longer-term use

Severe kidney or liver impairment can increase the concern about nausea and vomiting. The label calls for caution in severe impairment, while it does not require a dose adjustment for mild or moderate impairment. That does not create a home formula for calculating a reduced amount from a kidney test. [1]

A single acute-hepatitis case was reported during an uncontrolled extension, and a drug contribution could not be excluded. The development programme did not show a broader imbalance in liver-test signals. New jaundice, dark urine or persistent upper-abdominal pain needs medical review rather than being assumed to be ordinary nausea.

Longer follow-up comes from selected trial participants who continued treatment. It cannot establish that unrestricted daily use, much larger amounts or a different research formulation has the same safety profile.

Men, nasal spray and erectile-response concerns

The large safety percentages above come from women receiving the approved subcutaneous amount. Early male studies reported nausea and flushing after PT-141, but used different routes and amounts. They do not provide a reliable percentage risk for a man using a retail vial or nasal spray. [7]

A small study combined nasal PT-141 with sildenafil, but nineteen participants cannot establish broad combination safety. Adding tadalafil, sildenafil or an extra spray because the first effect seems weak is not a validated self-treatment schedule. [8]

An erection lasting four hours needs emergency care. Do not wait for the drug to wear off or use more sexual activity as the treatment. This is general priapism advice, not a claim that prolonged erections occurred at a known frequency with the supplied products. [9]

Injection reactions and product-quality problems

Spreading redness, swelling, red streaks or fever after an injection can indicate infection. Have those symptoms assessed promptly. A small bruise at a needle site and worsening inflammation spreading beyond it are different situations. [10]

Use sterile single-use equipment for prescribed injectable medicines and avoid re-entering a vial with a used needle or syringe. Stop using a preparation if its sterility is compromised. Correct handling reduces contamination risk; it does not certify the quality of the original research material. [11]

The supplied powder COA covers lot PL-2609-080, with two sampled vials from a batch of 250. It does not establish the finished nasal product's content, pump delivery or sterility. A high HPLC purity figure also does not measure the exact milligrams in every vial. [12]

The nasal documentation conflicts on both strength and formulation: written material refers to 10 mg in water with 0.9% benzyl alcohol, while product images show 30 mg, 150 mcg per spray, saline and methylparaben. The actual bottle's formulation needs confirmation before a reaction can be attributed to a particular ingredient.

There is no verified fixed usable period after preparing the powder. Refrigeration and a clear appearance do not establish that an opened research solution remains sterile or suitable for administration. The product documentation and redacted COA retain those limits.

When to seek urgent help

A repeated systolic reading above 180 or diastolic reading above 120 without those symptoms still needs prompt professional contact. If a wrong amount may have been used, seek poison-control or urgent medical advice rather than waiting for symptoms to establish the dose. In the United States, Poison Control is available at 1-800-222-1222; collapse, seizures or trouble breathing requires emergency services. [14]

Bring the product, lot, concentration, amount, timing and other medicines to the assessment when available. The calculator can help identify a decimal or concentration error, but it cannot decide whether a reaction is safe or whether another dose should be taken.